These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32691891)

  • 41. Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin.
    Kapetas AJ; Abuhelwa AY; Sorich MJ; McKinnon RA; Rodrigues AD; Rowland A; Hopkins AM
    AAPS J; 2021 Aug; 23(5):104. PubMed ID: 34467456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates.
    Ramsden D; Fung C; Hariparsad N; Kenny JR; Mohutsky M; Parrott NJ; Robertson S; Tweedie DJ
    Drug Metab Dispos; 2019 Oct; 47(10):1206-1221. PubMed ID: 31439574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of drug-drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.
    Jia G; Ren C; Wang H; Fan C
    BMC Pharmacol Toxicol; 2024 Jan; 25(1):4. PubMed ID: 38167223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model.
    Van den Bergh A; Snoeys J; De Zwart L; Ward P; Lopez-Gitlitz A; Ouellet D; Monshouwer M; Chien C
    Clin Pharmacokinet; 2020 Sep; 59(9):1149-1160. PubMed ID: 32338346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.
    Mukherjee D; Zha J; Menon RM; Shebley M
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):443-456. PubMed ID: 29427135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.
    Vieira ML; Zhao P; Berglund EG; Reynolds KS; Zhang L; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2012 Apr; 91(4):700-8. PubMed ID: 22398966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.
    Ueno T; Miyajima Y; Landry I; Lalovic B; Schuck E
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):455-466. PubMed ID: 33704920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
    Watanabe A; Kotsuma M
    Drug Metab Pharmacokinet; 2024 Apr; 55():101000. PubMed ID: 38458122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
    Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
    Marsousi N; Desmeules JA; Rudaz S; Daali Y
    Biopharm Drug Dispos; 2018 Jan; 39(1):3-17. PubMed ID: 28960401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
    Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
    Ji T; Chen X; Yeleswaram S
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
    Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
    Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
    Chen Y; Mao J; Hop CE
    Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
    Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.